**Core tip:** We provide an updated review of hepatitis A virus (HAV) coinfection among human immunodeficiency virus (HIV)-positive individuals, focusing on the epidemiology, clinical manifestations, and prevention for HAV infection. The reported outbreaks of acute hepatitis A among men who have sex with men and injecting drug users are summarized. Updated vaccination guidelines for prevention of HIV-positive individuals against HAV infection are presented. We also review the published data of effectiveness or efficacy of HAV vaccination studies and the different approaches to improvement of the serological responses to conventional HAV vaccines among HIV-positive individuals.

INTRODUCTION
============

Hepatitis A virus (HAV) is one of the most common infectious etiologies of acute hepatitis worldwide. According to the WHO estimates, HAV resulted in 13.7 million illnesses and 28000 deaths in 2010\[[@B1]\]. HAV is primarily transmitted fecal-orally *via* contaminated food or water, or through close contact with an infected person. With improved sanitation and provision of HAV vaccination, areas or populations with high HAV endemicity show patterns of declining endemicity, according to their socioeconomic backgrounds\[[@B2]\]. Based on the different age-specific HAV seroprevalence profiles, the world can be divided into countries of high, intermediate, low, and very low HAV endemicity\[[@B3]\]. In countries of high endemicity, most people acquire HAV in their early childhood and are immune to the virus. On the contrary, adults from low endemic areas are first exposed to HAV during travel to or residence in endemic areas, or being engaged in risky behaviors, such as contact with infected persons, being men who have sex with men (MSM), or using illicit drugs\[[@B2],[@B4]\].

Several outbreaks of acute HAV infection among the MSM and injecting drug users' (IDUs') communities have been reported in several developed countries of low endemicity for HAV infection. The duration of HAV viremia and stool shedding of HAV may be longer in HIV-positive individuals, increasing the window of opportunity for wider transmission of HAV to those engaged in risk behaviors. HAV vaccination is the most efficient approach to prevention of acquiring HAV infection. However, the seroconversion rates following the recommended standard 2-dose HAV vaccination schedule are lower among HIV-positive individuals compared to HIV-negative individuals, and the vaccination effectiveness among HIV-positive individuals is rarely investigated in the outbreak setting\[[@B5]\]. In this article, we review the epidemiology and clinical manifestations of acute HAV infection and HAV vaccination among HIV-positive individuals in the era of combination antiretroviral therapy (cART).

HAV VIROLOGY
============

HAV, first identified by Feinstone et al\[[@B6]\] in 1973, belongs to the *Hepatovirus* genus of the family *Picornaviridae*. The genome of HAV is a positive-strand RNA (range, 7470 to 7478 nucleotides) and encodes only a single open reading frame, which is translated into a polyprotein. The polyprotein is then cleaved by the virus-encoded protease (3C^pro^) to yield 8 viral proteins, including VP0, VP3, VP1-2A, 2B, 2C, 3AB, 3C^pro^, and RNA-dependent RNA polymerase (RDRP, 3D^pol^). The virus particle is composed of 3 proteins, VP0, VP1-2A, and VP3. During the assembly of the virus capsid, 2A will be removed from the VP1-2A by cellular protease or 3C^pro^, and at the final stage of maturation, VP0 will be cleaved into VP2 and VP4. Five copies of each protein will be assembled to form a pentamer, and 12 copies of the pentamer will form a virus capsid. Despite that there are some amino acid variations between different HAV strains, the detection of anti-HAV antibody is not as complicated as other RNA viruses due to the fact that HAV exists as a single serotype. Due to the advances of molecular technology, 7 unique genotypes (I to VII) of HAV are defined by analysis of a 168-base region, located between the C terminus of VP1 and N terminus of P2A\[[@B7]\]. These 7 genotypes exhibit less than 85% of sequence identity between genotypes and no more than 15% of divergence within a genotype, a criterion used for polioviruses, another member of the family *Picornaviridae*. However, further detailed analyses of other viral regions reveal that the genotypes II and VII should be reclassified as subtypes A and B of genotype II\[[@B8]\], and genotypes I and III could also be divided into subgenotypes A and B\[[@B9]\]. Four genotypes (I, II, III, and VII) are of human origin, and 3 (IV, V, VI) are of simian origin. Genotypes I and III are the most prevalent genotypes identified in humans. Subgenotypes IA and IB are often found in North and South Americas, Europe, China, and Japan\[[@B7]\]. Clusters within genotypes predominant in certain geographic regions have been reported, such as a group of subgenotype IA strains from the United States\[[@B10]\], and genotype II in the Netherlands, France, and Sierra Leone\[[@B7],[@B11]\]. However, in other regions, the presence of variant genotypes was reported in Europe and Japan, likely representing international spread from the endemic regions.

EPIDEMIOLOGY OF HAV INFECTION AMONG HIV-POSITIVE PATIENTS
=========================================================

HAV seroprevalence among HIV-positive patients
----------------------------------------------

Previous studies have shown higher seroprevalence and incidence of HAV infection among MSM compared to the general population\[[@B12]-[@B14]\], which were associated with oral-anal sex and the number of sexual contacts and partners\[[@B12],[@B15]-[@B20]\]. The HAV seroprevalence also increases with age, indicating the cohort effect\[[@B2],[@B12],[@B19],[@B21]\]. Unlike MSM, heterosexual men with risky sexual behaviors has been inconsistently associated with higher HAV seroprevalence. While a few studies reported a lower seroprevalence and incidence among heterosexual men with sexually transmitted diseases (STDs) compared to MSM\[[@B15],[@B16]\], others indicated that the risks for HAV infection among heterosexual men with STDs and MSM were similar\[[@B12],[@B19],[@B21]\]. IDUs also had a higher HAV seroprevalence than the general population\[[@B13],[@B14],[@B22],[@B23]\]. However, the high seroprevalence might not be solely attributable to needle contamination, since some reported similar elevation of the HAV seroprevalence between IDUs and non-injecting illicit drug users\[[@B22],[@B23]\].

Although the direct evidence on the correlation between contracting HIV and HAV was scarce, observational data suggested that HIV-positive individuals, especially MSM and IDUs, are at increased risk of acquiring HAV\[[@B24]\]. In addition, one small study including 15 HIV-positive individuals demonstrated that the duration of HAV viremia in HIV-positive individuals with acute hepatitis A was prolonged compared to that in HIV-negative individuals with acute hepatitis A, which may increase the probability of HAV transmission to others\[[@B25]\]. Several studies have reported the HAV seroprevalence among HIV-positive individuals and at-risk persons in areas of different HAV endemicities and vaccine coverage (Table [1](#T1){ref-type="table"})\[[@B12]-[@B23],[@B26]-[@B42]\]. In these studies, the HAV seroprevalence among HIV-positive individuals ranged from 15.1% in Taiwan to 96.3% in Iran\[[@B31],[@B35]\]. While studies conducted in countries of high HAV endemicity showed no differences in the HAV seroprevalence between HIV-positive and HIV-negative individuals\[[@B27]\], the seroprevalence in countries of low endemicity was higher among HIV-positive individuals compared to HIV-negative individuals\[[@B26],[@B30]\]. Among HIV-positive individuals, older age and injecting drug use were identified as the independent factors associated with seropositivity for HAV; the HAV seroprevalence was lower in HIV-positive MSM despite the at-risk sexual behaviors\[[@B29],[@B30],[@B33]-[@B36]\].

###### 

Seroprevalence of hepatitis A virus infection among human immunodeficiency virus-positive patients and at-risk populations

  **Ref**.                                                          **Location**                                                    **Study period**   **Study population**                               **Age (yr)**   **HIV-positive population**             **Other populations**                 **Associated factors[1](#T1FN1){ref-type="table-fn"} and comments**
  ----------------------------------------------------------------- --------------------------------------------------------------- ------------------ -------------------------------------------------- -------------- --------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------
  HIV-positive population                                                                                                                                                                                                                                                                              
  Nandwani et al\[[@B26]\]                                          London, United Kingdom                                          1993               255 men attending genitourinary clinics            32             41.3%                                   MSM, 32.4%                            No difference between homosexual and heterosexual men
  Heterosexuals, 30.0%                                                                                                                                                                                                                                                                                 
  Unknown HIV status, 26.4%                                                                                                                                                                                                                                                                            
  Fainboim et al\[[@B27]\]                                          Buenos Aires, Argentina                                         1994-1995          484 HIV-positive patients                          29             84.0%                                   HIV-positive MSM, 83.3%               High seroprevalence without difference between HIV-positive and HIV-negative individuals
  HIV-positive heterosexuals, 86.3%                                                                                                                                                                                                                                                                    
  HIV-positive IDUs, 85.7%                                                                                                                                                                                                                                                                             
  Blood donors, 82.4%                                                                                                                                                                                                                                                                                  
  Aloise et al\[[@B28]\]                                            Rio de Janeiro, Brazil                                          1988-2004          581 HIV-positive patients                          35             79.8%                                   NA                                    Older age and lower educational level
  Lee et al\[[@B29]\]                                               Tainan, Taiwan                                                  2000-2005          484 patients with recent diagnosed HIV infection   36             65.8%                                   HIV-positive MSM, 40.0%;              Seroprevalence increased with age and among heterosexuals
  HIV-positive heterosexuals, 85.2%                                                                                                                                                                                                                                                                    
  HIV-positive IDUs, 70.1%                                                                                                                                                                                                                                                                             
  Sun et al\[[@B30]\]                                               Taiwan                                                          2004-2007          1580 HIV-positive patients                         39             60.9%                                   HIV-positive MSM, 50.5%               Older age and injecting drug use
  HIV-positive heterosexuals, 79.3%                                 Higher seroprevalence in HIV-positive individuals                                                                                                                                                                                  
  HIV-positive IDUs, 62.0%                                                                                                                                                                                                                                                                             
  HIV-negative individuals, 48.0%                                                                                                                                                                                                                                                                      
  Davoudi et al\[[@B31]\]                                           Tehran, Iran                                                    2005-2006          247 HIV-positive patients                          36             96.3%                                   NA                                    
  Hoover et al\[[@B32]\]                                            6 major cities[2](#T1FN2){ref-type="table-fn"}, United States   2004-2007          627 HIV-positive MSM                               41             16.1%[3](#T1FN3){ref-type="table-fn"}   NA                                    Low HAV screening and vaccination rates (28.5%)
  Linkins et al\[[@B33]\]                                           Bangkok, Thailand                                               2006-2008          1291 MSM                                           27             32.4%[3](#T1FN3){ref-type="table-fn"}   HIV-negative MSM, 25.5%               Older age and lower education level
  Baek et al\[[@B34]\]                                              Seoul, South Korea                                              2008-2010          188 HIV-positive patients                          39             62.8%                                   HIV-positive MSM, 57.1%               Older age
  HIV-positive heterosexuals, 65.8%                                                                                                                                                                                                                                                                    
  Tseng et al\[[@B35]\]                                             Taipei, Taiwan                                                  2009-2010          1128 MSM                                           18-40          15.1%[3](#T1FN3){ref-type="table-fn"}   HIV-negative MSM, 7.4%                Older age
  No difference between HIV-positive and HIV-negative individuals                                                                                                                                                                                                                                      
  Kourkounti et al\[[@B36]\]                                        Athens, Greece                                                  2007-2011          897 HIV-positive MSM                               41             35.7%[3](#T1FN3){ref-type="table-fn"}   NA                                    Older age and being foreigners
  At-risk populations (MSM and IDUs)                                                                                                                                                                                                                                                                   
  Corey et al\[[@B15]\]                                             Seattle, United States                                          1977-1979          159 patients from STD clinics                      31             NA                                      MSM, 30.4% (annual incidence, 22%)    Oral-anal sexual contact
  Heterosexuals, 12.3% (annual incidence, 0%)                       Higher seroprevalence and incidence in MSM                                                                                                                                                                                         
  McFarlane et al\[[@B12]\]                                         Nova Scotia, Canada                                             1977-1978          421 patients from STD clinics                      25             NA                                      MSM, 42.4%                            Higher number of sex partners and older age
  Heterosexuals, 39.2%                                                                                                                                                                                                                                                                                 
  Blood donors, 12.6%                                                                                                                                                                                                                                                                                  
  Student nurses, 13.2%                                                                                                                                                                                                                                                                                
  Kryger et al\[[@B16]\]                                            Copenhagen, Denmark                                             1979               269 men with previous syphilis                     33             NA                                      MSM, 36.0%;                           More episodes of syphilis in younger MSM
  Heterosexual, 20.0%                                                                                                                                                                                                                                                                                  
  Coutinho et al\[[@B17]\]                                          Amsterdam, the Netherlands                                      1980-1982          689 MSM                                            31             NA                                      MSM, 42.0% (incidence, 14.0%)         Longer duration of homosexual activity
  Crofts et al\[[@B22]\]                                            Victoria, Australia                                             1990-1992          2175 prison entrants                               30             NA                                      IDU, 43.7%                            History of incarceration
  293 IDUs                                                          Prison entrants, 60.1%                                                                                                                                                                                                             
                                                                    Blood donors, 30.0%                                                                                                                                                                                                                
  Katz et al\[[@B18]\]                                              San Francisco and Berkeley, United States                       1992-1993          411 MSM                                            21             NA                                      MSM, 28.0%                            Sexual and drug-using behaviors
  Villano et al\[[@B13]\]                                           Baltimore, United States                                        1993-1994          294 MSM                                            NA             NA                                      MSM, 32.3%                            Increased risk for HAV infection in MSM and IDUs
  292 IDUs                                                          IDU, 66.4%                                                                                                                                                                                                                         
                                                                    Blood donors, 13.7%                                                                                                                                                                                                                
  Corona et al\[[@B19]\]                                            Rome, Italy                                                     1997               432 male patients from STD clinics                 NA             NA                                      MSM, 60.3%                            Older age and more sexual partner
  Heterosexual, 62.2%                                                                                                                                                                                                                                                                                  
  Ochnio et al\[[@B14]\]                                            Vancouver, Canada                                               1998               494 individuals from street outreach clinics       32             NA                                      MSM, 25.5%                            Increased risk for HAV infection in MSM and IDUs
  IDU, 42.6%                                                                                                                                                                                                                                                                                           
  Street youth, 6.3%                                                                                                                                                                                                                                                                                   
  Ross et al\[[@B21]\]                                              Birmingham, United Kingdom                                      2000               210 men attending genitourinary clinics            NA             NA                                      MSM, 23.0%; Heterosexual men, 32.0%   Ethnicity, older age, and history of sex in a sauna
  Diamond et al\[[@B37]\]                                           Washington, United States                                       1997-2000          833 MSM                                            15-29          NA                                      MSM, 21.0%                            Ethnicity, IDU, HBV and HIV infection
  Vaccination rate, 21%                                                                                                                                                                                                                                                                                
  Bialek et al\[[@B20]\]                                            7 major cities[4](#T1FN4){ref-type="table-fn"}, United States   1994-2000          2708 MSM                                           15-29          NA                                      MSM, 18.4%                            More male sex partners and unprotected anal sex
  O'Riordan et al\[[@B38]\]                                         London, United Kingdom                                          2004               395 MSM attending genitourinary clinics            NA             NA                                      MSM, 49.9%                            
  Van Rijckevorsel et al\[[@B39]\]                                  Amsterdam, the Netherlands                                      1992-2006          1697 hepatitis A patients                          NA             NA                                      Incidence, 0.97/1000 MSM              Clustered transmission in social MSM networks
  Removille et al\[[@B23]\]                                         Luxembourg                                                      2005               368 problem drug users                             NA             NA                                      IDUs, 57.1%                           
  nIDUs, 65.9%                                                                                                                                                                                                                                                                                         
  Bozicevic et al\[[@B40]\]                                         Zagreb, Croatia                                                 2006               360 MSM                                            27             NA                                      MSM, 14.2%                            
  Weerakoon et al\[[@B41]\]                                         Melbourne, Australia                                            2002-2011          3055 MSM                                           33             NA                                      MSM, 39.0%                            Vaccination levels over 40%-50% to prevent outbreaks
  Ali et al\[[@B42]\]                                               Sydney, Australia                                               1996-2012          14799 MSM                                          30             NA                                      MSM, 31.9% in 1996 to 63.8% in 2012   Vaccination rate, 9.8% in 1996 to 45.2% in 2012

Factors associated with HAV seropositivity were identified by bivariate or multivariable logistic regression analysis;

The 6 major cities included Atlanta, Chicago, Los Angeles, Miami, New York City, and San Francisco;

Only HIV-positive MSM were included;

The 7 major cities included Baltimore, Dallas, Los Angeles, Miami, New York City, San Francisco, and Seattle. HAV: Hepatitis A virus; IDUs: Injecting drug users; MSM: Men who have sex with men; NA: Not available; nIDUs: Non-injecting drug users; STD: Sexually transmitted disease.

Hepatitis A outbreaks in the MSM population
-------------------------------------------

In countries of low HAV endemicity, the majority of HAV-seronegative adults remain susceptible to acute HAV infection. Outbreaks of acute hepatitis A are often caused by introduction of HAV through contaminated foods and person-to-person transmission\[[@B2]\]. Numerous outbreaks of acute hepatitis A have been reported in the MSM population through sexual contacts, which are summarized in Table [2](#T2){ref-type="table"}\[[@B43]-[@B70]\]. Since the early 1980s, outbreaks of acute hepatitis A among MSM have been described in Denmark\[[@B43]\], Sweden\[[@B44]\], the United Kingdom\[[@B45]\], and the United States\[[@B61],[@B62]\]. The incidence of acute HAV infection among MSM peaked in the 1990s, and the affected countries included the United Kingdom\[[@B46],[@B47],[@B49],[@B51]\], the Netherlands\[[@B48]\], Norway\[[@B50]\], the United States\[[@B63],[@B65],[@B66]\], Canada\[[@B64]\] and Australia\[[@B67]-[@B70]\]. One of the largest epidemics of acute hepatitis A occurred in Sydney, Australia, where 2 outbreaks affected 323 and 186 MSM during 1991-1992 and 1995-1996, respectively\[[@B69]\]. Since 2015, Taiwan reported a large outbreak involving more than 1000 indigenous cases, with more than 70% of the affected individuals being MSM\[[@B71]\]. While the HAV vaccine was licensed and recommended for MSM since the mid-1990s\[[@B47]\], the emergence of HAV infection continued to pose a health threat to MSM in several developed European countries during the 2000s, including Italy\[[@B52],[@B54],[@B55],[@B60]\], Denmark\[[@B53]\], Spain\[[@B56],[@B58]\], Poland\[[@B57]\], and the United Kingdom\[[@B59]\].

###### 

Outbreaks of acute hepatitis A in the men who have sex with men population

  **Ref**.                                                         **Location**                             **Study period**   **Case number**   **Male**   **MSM**   **HIV-positive patients**   **Age (yr)**   **Risk factors[1](#T2FN1){ref-type="table-fn"} and comments**
  ---------------------------------------------------------------- ---------------------------------------- ------------------ ----------------- ---------- --------- --------------------------- -------------- -------------------------------------------------------------------------------------
                                                                   Europe                                                                                                                                        
  Høybye et al\[[@B43]\]                                           Copenhagen, Denmark                      1977-1978          45                45         21        NA                          29             
  Christenson et al\[[@B44]\]                                      Stockholm, Sweden                        1979-1980          145               145        145       NA                          NA             Multiple partners and oral-anal sexual contact
  Mindel et al\[[@B45]\]                                           London, United Kingdom                   1980               24                NA         23        NA                          NA             HAV infection was associated with homosexual activity
  Kani et al\[[@B46]\]                                             London, United Kingdom                   1989-1990          7000              NA         41        NA                          NA             Oral-anal sexual contact
  Atkins et al\[[@B47]\]                                           London, United Kingdom                   1989-1992          206               121        65        NA                          NA             Oral-anal sexual contact and sexual promiscuity
  Leentvaar-Kuijpers et al\[[@B48]\]                               Amsterdam, the Netherlands               1992-1993          293               NA         39        NA                          NA             Visiting saunas and darkrooms
  Walsh et al\[[@B49]\]                                            Thames region, United Kingdom            1995               481               NA         58        NA                          NA             Oral-anal and digital-rectal intercourse
  Stene-Johansen et al\[[@B50]\]                                   Oslo, Norway                             1995-1998          26                26         26        NA                          NA             
  Bell et al\[[@B51]\]                                             London and East Sussex, United Kingdom   1997               48                NA         41        NA                          NA             Eating shellfish and sex in gay saunas
  Manfredi et al\[[@B52]\]                                         Bologna, Italy                           1999-2004          122               104        81        11                          28             Unprotected sexual contact
  Mazick et al\[[@B53]\]                                           Copenhagen, Denmark                      2004               18                18         18        NA                          NA             Casual sex and sex in gay saunas
  Girardi et al\[[@B54]\]                                          Rome, Italy                              2002-2008          473               368        115       57                          25-64          Same gender sex
  Routine HIV test in HAV-infected patients should be considered                                                                                                                                                 
  Bordi et al\[[@B55]\]                                            Rome, Italy                              2008-2010          162               143        34        14                          36             Monophyletic HAV strain sustained the outbreak
  Tortajada et al\[[@B56]\]                                        Barcelona, Spain                         2002               48                47         NA        28%                         31             
                                                                                                            2003-2004          60                60         NA        24%                         32             
                                                                                                            2008-2009          189               185        NA        21%                         33             
  Dabrowska et al\[[@B57]\]                                        Warsaw, Poland                           2007-2008          860               NA         50        6                           28             No difference in disease severity between HIV-positive and HIV-negative individuals
  Tortajada et al\[[@B58]\]                                        Barcelona, Spain                         2008-2009          150               126        87        NA                          33             
  Sfetcu et al\[[@B59]\]                                           Northern Ireland, United Kingdom         2008-2009          38                36         26        NA                          29             The outbreak strain was indistinguishable from that in Czech Republic
  Taffon et al\[[@B60]\]                                           Tuscany, Italy                           2008               240               NA         32%       NA                          NA             A unique circulating HAV strain
                                                                   North America                                                                                                                                 
  Kosatsky et al\[[@B61]\]                                         Anchorage, Alaska                        1982-1983          17                17         17        NA                          19-31          
  Desenclos et al\[[@B62]\]                                        Florida, United States                   1988-1989          311               69         26        NA                          NA             
  Henning et al\[[@B63]\]                                          New York, United States                  1991               180               180        62        NA                          20-49          Anonymous sex partner, group sex, oral-anal and digital-rectal intercourse
  Allard et al\[[@B64]\]                                           Montréal, Canada                         1996-1997          376               376        376       NA                          33             Vaccination campaign achieving 20%-41% coverage in MSM decreased incidence rapidly
  Finton et al\[[@B65]\]                                           Atlanta, United States                   1996               222               NA         75%       NA                          NA             Vaccination campaign in MSM decreased reported cases
  Cotter et al\[[@B66]\]                                           Ohio, United States                      1998-1999          136               118        47        NA                          33             Contact with hepatitis A cases
                                                                   Asia-Pacific region                                                                                                                           
  Stewart et al\[[@B67]\]                                          Melbourne, Australia                     1991               495               407        210       NA                          NA             Sexual and social contact
  Stokes et al\[[@B68]\]                                           Sydney, Australia                        1991-1992          570               515        330       NA                          31             Sexual contact was the most reported contact type
  Ferson et al\[[@B69]\]                                           Sydney, Australia                        1991-1996          1138              991        587       NA                          30             Household or sexual contact
  Delpech et al\[[@B70]\]                                          Sydney, Australia                        1997-1999          354               265        139       NA                          32             
  Chen et al\[[@B71]\]                                             Taiwan                                   2015-2016          \> 1000           NA         \> 70%    \> 60%                      NA             A total of 1296 cases reported as of February, 2017

Risk factors of acquiring HAV infection were identified by case-control studies. HAV: Hepatitis A virus; MSM: Men who have sex with men; NA: Not available.

The duration of outbreaks of acute hepatitis A among MSM were mostly curtailed at 2 years; however, the outbreak in Canada extended from December 1994 to February 1998\[[@B64]\]. The cyclical outbreaks were noted in Australia during 1991-1996\[[@B69]\] and in Spain during 1989-2010\[[@B56]\], which might be facilitated by the continuous circulation of particular HAV strains in the MSM population\[[@B50],[@B55],[@B60]\]. The predominant circulating HAV strains among MSM belonged to genotype IA\[[@B50],[@B55],[@B59],[@B60],[@B72]\]. The patients contracting HAV during the outbreaks were mostly young adults with a mean or median age of 28-36 years\[[@B55],[@B57]\]. HAV was recognized as being transmitted among MSM through sexual contacts\[[@B73]\], and case-control studies have identified several associated factors such as having anonymous sex partners, group sex, oral-anal and digital-rectal intercourse\[[@B63]\], contact with patients with acute hepatitis A\[[@B66]\], having sex in gay saunas\[[@B51],[@B53]\], and visiting saunas and darkrooms\[[@B48]\]. In light of the risky sexual behavior, the largest HAV vaccination campaign for MSM was launched in Montréal, in which 9500-15000 first doses of HAV vaccine were administered to achieve a coverage rate between 20% and 41%. However, the decrease in the incidence of acute hepatitis A shortly after the vaccination campaign might indicate the relatively late implementation of HAV vaccination and the natural decline after herd immunity was established at the end of the outbreak\[[@B64]\]. The vaccination campaigns targeting MSM in Atlanta and Barcelona recruited 3,000 persons, which resulted in a 16% decrease of reported acute hepatitis A cases\[[@B56],[@B65]\].

Coinfections with HAV and HIV were identified during the 2000s in Italy\[[@B52],[@B54],[@B55]\], Spain\[[@B56]\], and Poland\[[@B57]\]. Most HAV/HIV-coinfected individuals were males with known HIV status, while others were found to be HIV-positive concomitantly with acute HAV infections\[[@B52],[@B54]-[@B57]\]. Among all male patients who received a diagnosis of acute hepatitis A during 2002-2008 in Italy, 15.2% (56/368) were HIV-positive\[[@B54]\]. After excluding those without available HIV serology, the HIV seroprevalence among was 27.6%\[[@B54]\]. The high proportion of HAV/HIV coinfection in the areas of low HAV endemicity highlights the importance of routine HIV testing in patients with acute hepatitis A\[[@B54]\].

Hepatitis A outbreak in the IDU population
------------------------------------------

Outbreaks of acute hepatitis A in the IDU population have been reported since 1970s as the numbers of IDUs increased\[[@B74]\]. The studies of outbreaks of acute hepatitis A among IDUs are summarized in Table [3](#T3){ref-type="table"}\[[@B74]-[@B88]\]. During 1970-1979, the cyclic occurrence of outbreaks of acute hepatitis A in Sweden suggested a continuously increasing pool of susceptible young IDUs in the closed communities\[[@B74]\]. The outbreaks were mostly described in Europe\[[@B75]-[@B78]\] and the United States\[[@B82],[@B83],[@B85]\] in the 1980s and 1990s, but were seldom described after the early 2000s\[[@B79]-[@B81],[@B86]\]. Up to 492 IDUs were infected with HAV in Norway between 1995 and 1996\[[@B77]\]. In Terni, Italy; 47 cases of acute hepatitis A were reported during 2002-2003, among which included 35 IDUs and 2 HIV-positive individuals. The most recent outbreak of acute HAV infection among IDUs was described in Israel during 2012-2013, which occurred in IDUs and homeless adults with subsequent spread to the general population in Tel Aviv, despite the nation-wide implementation of universal toddler's vaccination in 1999\[[@B88]\].

###### 

Outbreaks of acute hepatitis A in the injecting drug user population

  **Ref**.                         **Location**              **Study period**   **Total patients**   **IDU**   **HIV-positive individuals**   **Age (yr)**   **Risk factors[1](#T3FN1){ref-type="table-fn"} and comments**
  -------------------------------- ------------------------- ------------------ -------------------- --------- ------------------------------ -------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
                                   Europe                                                                                                                    
  Widell et al\[[@B74]\]           Malmo, Sweden             1970-1979          323                  188       NA                             NA             
  Sundkvist et al\[[@B75]\]        Helsingborg, Sweden       1983-1984          36                   32        NA                             18-35          The outbreak was associated with intrarectal transportation of illicit drugs
  Leino et al\[[@B76]\]            Helsinki, Finland         1994-1995          238                  131       NA                             31             The outbreak was associated with intrarectal transportation of illicit drugs
  Stene-Johansen et al\[[@B77]\]   Oslo, Norway              1995-1996          621                  492       NA                             NA             The outbreak was associated with needle sharing
  O'Donovan et al\[[@B78]\]        United Kingdom            1998-1999          27                   14        NA                             25             
  Syed et al\[[@B79]\]             Bristol, United Kingdom   2000               123                  69        NA                             25             The outbreak was associated with parenteral transmission from contaminated illicit drugs; HAV vaccination of IDUs decreased the reported cases
  Roy et al\[[@B80]\]              Aberdeen, Scotland        2000-2002          106                  74        NA                             NA             Not washing hands after using the toilet, or before preparing food or drugs, sharing needles/syringes, and injecting contact with jaundiced persons
  Spada et al\[[@B81]\]            Terni, Italy              2002-2003          47                   35        2                              34             Contact with jaundiced persons, but not related to injecting practices; HAV vaccination of IDUs decreased the reported cases
                                   North America                                                                                                             
  Harkess et al\[[@B82]\]          Oklahoma, United States   1984-1987          79                   42        NA                             23-27          
  Jenkerson et al\[[@B83]\]        New York, United States   1986-1987          256                  70        NA                             NA             
  Jin et al\[[@B84]\]              Canada                    1987-1989          65                   59        NA                             NA             
  Hutin et al\[[@B85]\]            Iowa, United States       1996-1997          158                  9.7%      NA                             NA             Methamphetamine injection, sharing methamphetamine use, using brown methamphetamine, and needle sharing
  Vong et al\[[@B86]\]             Florida, United States    2001-2002          403                  11%       NA                             32             HAV vaccination in jail decreased the reported cases
                                   Asia-Pacific region                                                                                                       
  Shaw et al\[[@B87]\]             Queensland, Australia     1997               875                  118       NA                             NA             Sharing of instruments for smoking marijuana
  Manor et al\[[@B88]\]            Tel-Aviv, Israel          2012-2013          75                   9         NA                             33             

Risk factors of acquiring HAV infection were identified by case-control studies. HAV: Hepatitis A virus; HIV: Human immunodeficiency virus; IDU: Injecting drug user; NA: Not available.

The outbreaks of acute hepatitis A among IDUs mainly lasted between 1 and 2 years, and young patients with a mean or median age of 20-34 years were predominantly affected\[[@B74],[@B81]\]. HAV could be transmitted fecal-orally through poor personal hygiene and living conditions, or percutaneously through contamination of illicit drugs or injecting equipment by fecal materials or blood\[[@B81]\]. Three case-control studies identified not washing hands after using the toilet or before preparing food, not washing hands prior to preparing drugs, sharing of needles or syringes, use of contaminated illicit drugs, and contact with jaundiced persons to be factors associated with acute hepatitis A in IDUs\[[@B80],[@B81],[@B85]\]. To curb the epidemic of acute hepatitis A, HAV vaccination programs were implemented in the United Kigndom\[[@B79]\], Norway\[[@B89]\] and Italy\[[@B81]\], and harm reduction program by providing clean injecting equipment was implemented in Switzerland\[[@B90]\].

CLINICAL MANIFESTATIONS OF ACUTE HAV INFECTION
==============================================

The incubation period of acute HAV infection is 2.5 to 5 wk\[[@B91]\]. The typical symptoms of acute hepatitis A include fatigue, malaise, nausea, vomiting, anorexia, fever, and right upper quadrant pain. The frequencies of symptoms or signs of acute hepatitis A are listed in Table [4](#T4){ref-type="table"}\[[@B92]-[@B96]\]. While most of acute HAV infections are self-limited, the severity of the symptoms may vary with age and concurrent comorbidities, particularly chronic viral hepatitis. Acute HAV infection is usually silent or subclinical in children, but approximately 30% of the infected patients older than 6 years have symptoms including hepatitis, jaundice, and abdominal pain\[[@B97]\]. Less than 25% of the patients have diarrhea though HAV is transmitted through fecal-oral route\[[@B98]\]. The data on the symptoms of acute hepatitis A among HIV-positive individuals are limited, and the study by Ida et al\[[@B25]\] of 15 HIV-positive and 15 HIV-negative individuals with acute hepatitis A suggested no differences in the frequency and severity of clinical symptoms of acute hepatitis A between the two groups.

###### 

Clinical symptoms and signs of patients with acute hepatitis A infection\[[@B92]-[@B96]\]

  **Symptoms**           **Frequency**
  ---------------------- ---------------
  Asymptomatic           14%
  Fever                  48%-87%
  Nausea/vomiting        56%-88%
  Anorexia               66%-96%
  Fatigue/malaise        49%-80%
  Upper abdominal pain   42.5%-82%
  Diarrhea               8%-23%
  Signs                  
  Jaundice               24%-99%
  Hepatomegaly           7%-78%
  Splenomegaly           18%-30%

Patients with acute hepatitis A usually have significantly elevated levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin. In previous studies, the average peak levels of total bilirubin were 7-8 mg/dl and the levels of AST and ALT were higher than 1000 IU/L\[[@B25],[@B92],[@B93],[@B98]-[@B100]\]. Alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (γ-GT) are also elevated in patients with acute hepatitis A. Resolution of the abnormal biochemical tests generally occurs within 1 to 6 wk after the onset of the illness\[[@B99]\]. Approximately 85% of the patients who are infected with HAV have full clinical and biochemical recovery within 3 mo and nearly all have a complete recovery by 6 mo\[[@B92]\]. The study by Ida et al\[[@B25]\] reported lower elevations in total bilirubin, AST, and ALT in HIV-positive individuals during acute hepatitis A than HIV-negative individuals, which were considered to be related to the weaker immune responses in HIV-positive patients or clonal spreading of a specific HAV strain that was able to escape from immunity in the study. Regulatory T cells (Tregs) normally suppress the T-cell responses directed against hepatitis viruses and down-regulate the immune reaction that is responsible for liver damage in viral hepatitis\[[@B101]\]. The study by Choi et al\[[@B102]\] suggested a decrease in Tregs leading to a severe liver injury during acute hepatitis A. HIV-positive individuals however are known to have high Tregs, compared to their HIV-negative counterparts, hence they may experience less severe injury during acute hepatitis A\[[@B103]\]. On the other hand, Ida et al\[[@B25]\] reported higher levels of ALP and γ-GT during acute hepatitis A in HIV-positive individuals than HIV-negative patients. Biliary tract is not the primary target of HAV infection. Lymphocytic cholangitis is rarely seen with acute HAV infection\[[@B104]\]. However, HIV-related cholangitis or cholangiography is a well-recognized late complication of acquired immunodeficiency syndrome (AIDS). Opportunistic infections such as cytomegalovirus infection or cryptosporidiosis may also cause cholangitis. HIV is also able to cause direct cytopathic effects on the biliary tract mucosa. Hence, the higher levels of ALP and γ-GT observed in HIV-positive patients with acute hepatitis A may be explained by multiple factors other than the liver injury caused by HAV itself.

In the general population, stool shedding of HAV antigen can be detected 19 d before the peak elevation of ALT levels and continue for at least 25 d\[[@B105]\] and even up to 80 d\[[@B106]\]. The duration of viremia is estimated to last around 20 to 40 d\[[@B25],[@B106],[@B107]\] and even longer than 3 mo\[[@B108]\]. In the study by Ida et al\[[@B25]\], the median duration of HAV viremia in HIV-positive individuals with acute hepatitis A was 53 d, which was longer than that of HIV-negative individuals. A longer duration of HAV viremia may be related to impaired host immunity\[[@B100]\]. Besides, the relationship between duration of viremia and specific HAV genotypes is still inconclusive\[[@B106],[@B107]\]. The comparisons of clinical manifestations of acute hepatitis A between HIV-positive and HIV-negative individuals are summarized in Table [5](#T5){ref-type="table"}\[[@B25],[@B57],[@B91]-[@B93],[@B95],[@B98]-[@B100],[@B105]-[@B109]\].

###### 

Comparison of clinical manifestations of hepatitis A virus between human immunodeficiency virus-positive patients or human immunodeficiency virus-negative patients with acute hepatitis A

                                          **HIV-positive patients**    **HIV-negative patients**
  --------------------------------------- ---------------------------- ------------------------------------------------------
  Natural course of acute HAV infection                                
  Incubation period (wk)                  NA                           2.5-5\[[@B91]\]
  Duration of stool shedding (d)          NA                           25 (HAV antigen)\[[@B105]\]
  81 (HAV RNA)\[[@B106]\]                                              
  Duration of viremia (d)                 53 (10-89)\[[@B25]\]         22-95\[[@B25],[@B106]-[@B108]\]
  Laboratory findings                                                  
  Peak T-bilirubin (mg/dL)                5.1-5.9\[[@B25]\]            5.7-8.7\[[@B25],[@B92],[@B93],[@B95],[@B98],[@B99]\]
  Peak AST (IU/L)                         929-1339\[[@B25],[@B57]\]    1231-2271\[[@B25],[@B92],[@B93],[@B99]\]
  Peak ALT (IU/L)                         1995-2368\[[@B25],[@B57]\]   1079-3442\[[@B25],[@B92],[@B93],[@B99],[@B100]\]
  Duration of elevated AST/ALT (d)        63 ± 38\[[@B109]\]           51\[[@B92]\]
  Peak ALP (IU/L)                         807\[[@B25],[@B57]\]         228-396\[[@B25],[@B92]\]

HIV: Human immunodeficiency virus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HAV: Hepatitis A virus; NA: Not available.

Other atypical presentations of acute hepatitis A include renal insufficiency and relapsing hepatitis\[[@B93]\], which are usually present in children. Some individuals experienced a prolonged hepatitis (5.8%)\[[@B93]\] or cholestasis (6.8%), especially in the presence of hepatitis B virus\[[@B94]\]. Severe hepatic failure is rare and occurs more commonly in patients with underlying diseases or advanced age. Reported case fatality rates were 0.1% in infants and children, 0.45% in those aged 15 to 39 years, and 1.1% in those aged \> 40 years. Patients with chronic hepatitis C virus (HCV) infection have a substantial risk of fulminant hepatitis and death associated with HAV superinfection\[[@B110]\]. HIV-positive individuals acquire HAV infection mostly in their adulthood and often have other underlying liver disease\[[@B25],[@B57]\], which may increase the risk of hepatic failure and fatality caused by HAV. Therefore, prevention by HAV vaccination is important, especially for the HIV/HCV-coinfected individuals.

HAV VACCINATION AND FACTORS ASSOCIATED WITH IMMUNOGENICITY AND PERSISTENT PROTECTION
====================================================================================

Vaccine immunogenicity and factors associated with immunogenicity
-----------------------------------------------------------------

HAV vaccination is not universally recommended for HIV-positive individuals but specifically for those with increased risks of exposure (such as from injecting drug use, oral-anal sex, travel to or residence in endemic areas, frequent clotting factor or blood transfusions) or with increased risks of fulminant disease (such as those with chronic hepatitis) (Table [6](#T6){ref-type="table"})\[[@B111]-[@B114]\]. Of the two types of HAV vaccines that are currently available internationally, the live attenuated vaccine (based on H2 or LA-1 HAV strains and manufactured as well as mainly used in China or India) and the inactivated HAV vaccine (based on clinical trials since 1991 and licensed in the United States since 1995), only the latter is recommended for HIV-positive individuals. There are 3 formulations of inactivated HAV vaccines that have been assessed in HIV-positive individuals with varying degrees of immunodeficiency as shown in Table [7](#T7){ref-type="table"}\[[@B115]-[@B129]\]. Although different specific anti-HAV IgG titers have been used to define seroconversion (10, 18, 20, or 33 mIU/mL), the majority of these studies have adopted 20 mIU/ml as the surrogate titer for seroprotection.

###### 

Hepatitis A virus vaccination recommendations by the British human immunodeficiency virus Association, the European AIDS Clinical Society, the US Advisory Committee for Immunization Practices and the World Health Organization

  **Health Authority**                                                                                                                                                                                           **Target candidates**                                                                                                                                                                                                                                                                                              **Dosing Schedule**                                                                                                                      **Comments**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BHIVA\[[@B111]\]                                                                                                                                                                                               Household and sexual contacts of infected persons                                                                                                                                                                                                                                                                  Monovalent HAV vaccine recommended                                                                                                       We support the BHIVA's recommendations of targeted vaccination during outbreaks and of stratifying dosing schedule by CD4 counts, particularly administering a 3-dose schedule for those with lower CD4 counts. Despite waning antibody levels, we could not find evidence to justify routine boosters every 10 yr for those at risk. It may be preferable to follow antibody titers and revaccinate seroreverters
  Travellers                                                                                                                                                                                                     Patients with CD4 counts \> 350 cells/mm^3^ should be offered 2 vaccine doses at 0 and 6 mo                                                                                                                                                                                                                                                                                                                                                                 
  MSM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Injecting and non-injecting drug users                                                                                                                                                                         Patients with CD4 counts \< 350 cells/mm^3^ should receive 3 vaccine doses at 0, 1, and 6 mo                                                                                                                                                                                                                                                                                                                                                                
  Individuals at risk of infection during outbreaks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Those with occupational exposure to HAV (*e.g*., laboratory workers, sewage workers)                                                                                                                           Patients at continued risk of exposure receive a boosting vaccine dose every 10 yr                                                                                                                                                                                                                                                                                                                                                                          
  Hemophiliacs                                                                                                                                                                                                   Following a significant exposure, HIV-positive contacts who are HAV-seronegative receive post-exposure prophylaxis with the HAV vaccine, with the first dose given as soon as possible and within 14 d of exposure; if the CD4 count is \< 200 cells/mm^3^, they should also receive human normal immunoglobulin                                                                                                                                            
  Residents of care institutions, and their care givers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  EACS\[[@B112]\]                                                                                                                                                                                                Travellers                                                                                                                                                                                                                                                                                                         Vaccinate if seronegative. Did not specify how                                                                                           Shorter list of at risk candidates for vaccination. Our review supports their recommendation to check antibody titers in individuals with risk profile to guide the need for primary or booster vaccinations
  MSM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  IDUs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Active hepatitis B or C infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ACIP\[[@B113]\]                                                                                                                                                                                                MSM                                                                                                                                                                                                                                                                                                                Monovalent vaccine formulations should be administered in a 2-dose schedule at either 0 and 6-12 mo (Havrix), or 0 and 6-18 mo (Vaqta)   Unlike BHIVA, in addition to the monovalent vaccine formulations, ACIP also recommends the combined hepatitis A and B vaccine
  Injection or non-injection illicit drugs users                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Persons working with HAV-infected primates or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  with HAV in a research laboratory setting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Persons with chronic liver disease                                                                                                                                                                             If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 mo; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21-30 followed by a booster dose at 12 mo                                                                                No mention of the need to follow antibody titers or booster vaccines or the application of immunization during outbreaks                 
  Persons who receive clotting factor concentrates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Travellers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Close personal contact (*e.g*., household or regular babysitting) with an international adoptee during the first 60 d after arrival in the United States from a country with high or intermediate endemicity                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  WHO\[[@B114]\]                                                                                                                                                                                                 Travellers                                                                                                                                                                                                                                                                                                         Inactivated vaccine: 2 doses, the second dose normally 6 mo after the first. If needed, this interval may be extended to 18-36 mo        Does not specify whether all HIV-positive persons should be considered as immunosuppressed patients although evidence from Table [5](#T5){ref-type="table"} suggests that except for the duration of viremia acute HAV is not more severe in HIV-positive compared to HIV-negative patients
  Immunosuppressed patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Patients with chronic liver disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

HAV: Hepatitis A virus; HIV: Human immunodeficiency virus; IDUs: Injecting drug users.

###### 

Primary response rates and predictors of seroconversion after hepatitis A virus vaccination in human immunodeficiency virus-positive patients

  **Ref**.                                             **Dates**                **Design/Country**                                      **No. of patient[1](#T7FN1){ref-type="table-fn"}**   **HAV/dosing schedules (mo)**         **CD4, cells/mm[3](#T7FN3){ref-type="table-fn"}**   **PVL, log~10~, copies/mL**             **ART**   **Timing of response[2](#T7FN2){ref-type="table-fn"}, mo/cut-off[3](#T7FN3){ref-type="table-fn"}, mIU/mL/assay**   **Response rate (%): ITT/PP**   **Predictors and comments[4](#T7FN4){ref-type="table-fn"}**
  ---------------------------------------------------- ------------------------ ------------------------------------------------------- ---------------------------------------------------- ------------------------------------- --------------------------------------------------- --------------------------------------- --------- ------------------------------------------------------------------------------------------------------------------ ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tseng et al\[[@B115]\]                               2009-2010                Prospective, Taiwan                                     Standard 2-dose                                      HAVRIX 1440 U/                        Mean, 538                                           Mean, 2.5                               67.1%     12, 18/20, a. CIA (ARCHITECT HAVAb-IgG) b. ELISA (ETIAB- HAVK PLUS)                                                12 m (CIA): 75.7/81.7           MSM only study; Higher baseline CD4 and suppressed PVL; 3 doses over 2 doses
  All 126;                                             2 doses (0, 6)           12 m (ELISA): NA/88.6                                                                                                                                                                                                                                                                                                                                                                                       
  CD4 matched, 114                                                              18 m (ELISA): NA/86.6                                                                                                                                                                                                                                                                                                                                                                                       
  3-dose                                               HAVRIX 1440/             Mean, 452                                               Mean, 3                                              58.2%                                 12 m (CIA): 77.8/81.8                                                                                                                                                                                                                                    
  All, 213;                                            3 doses (0, 1, 6)        12 m (ELISA): NA/89.2                                                                                                                                                                                                                                                                                                                                                                                       
  CD4 matched, 114                                                              18 m (ELISA): NA/86.9                                                                                                                                                                                                                                                                                                                                                                                       
  Standard 2-dose                                      HAVRIX 1440/             NA                                                      NA                                                   NA                                    12 m (CIA): 88.5/97.9                                                                                                                                                                                                                                    
  HIV-negative, 193                                    2 doses (0, 6)           12 m (ELISA): NA/100                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                18 m (ELISA): NA/100                                                                                                                                                                                                                                                                                                                                                                                        
  Mena et al\[[@B116]\]                                1997-2009                Retrospective, Spain                                    Standard 2-dose, 241                                 HAVRIX 1440/                          Median, 531                                         55.3%[5](#T7FN5){ref-type="table-fn"}   61.4%     10-16/20, CIA (Advia Centaur)                                                                                      NA/80.7                         Higher CD4/CD8 ratio; 2 or more doses compared to 1 dose only; female; no HCV infection
  (0, 6-12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Accelerated, 41                                      TWINRIX 720/             Median, 543                                             73.2%                                                80.5%                                 5/20, CIA (Advia Centaur)                           NA/70.7                                                                                                                                                                                              
  (0, 7, 21 d, 6-12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Jimenez et al\[[@B117]\]                             2002-2008                Retrospective, United States                            Standard 2-dose, 125                                 HAVRIX 1440/ (0, 6-12)                Median, 410                                         Median, 3.1                             70.0%     Variable/\< 0.8 signal relative to cut-off, CIA (Vitros ECi)                                                       NA/54                           Higher baseline CD4 count and suppressed PVL
  101                                                  TWINRIX 720/             NA/53                                                                                                                                                                                                                                                                                                                                                                                                       
  (0, 1, 6-12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kourkounti et al\[[@B118]\]                                                   Retrospective, Greece                                   cART-experienced, 63                                 HAVRIX 1440 or Vaqta 50/ (0, 6-12)    628                                                 \< 1.7                                  100.0%    7-13/20, ELFA (VIDAS)                                                                                              NA/78                           Higher baseline CD4 count
  cART-naïve, 50                                       472                      3.9                                                     0.0%                                                 NA/76                                                                                                                                                                                                                                                                                          
  Weinberg et al\[[@B119]\]                            1994-2010                Prospective observational, United States                Hormone oral contraceptive, 13                       2 doses (0, 6) or 3 doses (0, 2, 6)   478                                                 47%[5](#T7FN5){ref-type="table-fn"}     78.0%     NA/20, ELISA (Mediagnost)                                                                                          NA/62                           Women only study; Higher baseline CD4 count and suppressed PVL
  No contraceptive, 149                                NA/51                                                                                                                                                                                                                                                                                                                                                                                                                                
  Launay et al\[[@B120]\]                              2003-2005                Randomized controlled trial, France                     Standard 2-dose, 49                                  HAVRIX 1440/ (0, 6)                   Median, 355                                         Median, \< 1.7                          78.0%     6-18/20, ELISA (ETIAB- HAVK PLUS)                                                                                  6 m: 44.9/46.8                  Absence of tobacco smoking
  7 m: 69.4/72.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  18 m: 61.2/69.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  3-dose, 46                                           HAVRIX 1440/ (0, 1, 6)   Median, 351                                             Median, \< 1.7                                       83.0%                                 6 m: 69.6/74.4                                                                                                                                                                                                                                           
  7 m: 82.6/88.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  18 m: 78.3/85.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Overton et al\[[@B121]\]                             1997-2004                Retrospective, United States                            1 or 2-dose, 268                                     HAVRIX 1440/                          Mean, 447                                           Mean, 2.9                               67.5%     NA/NA                                                                                                              NA/49.6                         Male; PVL \< 1000 copies/mL
  NA (1 or 2 doses)                                    ELISA (Not specified)                                                                                                                                                                                                                                                                                                                                                                                                                
  Weissman et al\[[@B122]\]                            2001-2003                Retrospective, United States                            Standard 2-dose, 138                                 HAVRIX 1440/                          Mean, 424                                           NA                                      81.9%     6-13/18, EIA (Abbot IMx HAV Ab)                                                                                    48.6 (67/138)                   Female; CD4 count at vaccination \> 200 cells/mm[3](#T7FN3){ref-type="table-fn"}
  (0, 6-12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wallace et al\[[@B123]\]                             1997-1998                Randomized controlled trial, United States              Standard 2-dose, HIV-positive, 55                    Vaqta 50/ (0, 6)                      Mean, 457.5                                         4.52                                    76.0%     1, 6, 7, 12/10, Quantitative modified HAVAb assay (NA)                                                             1 m: NA/61,                     100% of subjects with CD4 counts ≥ 300 cells/mm[3](#T7FN3){ref-type="table-fn"} seroconverted
  CD4 \< 300/ 300+, 48/74                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  7 m: NA/94,                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  CD4 \< 300/ 300+, 87/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  12 m: NA/90,                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  CD4 \< 300/ 300+, 80/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Standard 2-dose, HIV-negative, 72                    Vaqta 50/ (0, 6)         NA                                                      NA                                                   NA                                    1 m: NA/90                                                                                                                                                                                                                                               
  7 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  13 m: NA/90                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kemper et al\[[@B124]\]                              1995-1997                Double-blind, placebo-controlled trial, United States   Standard 2-dose, HIV-positive, 48                    HAVRIX 1440/ (0, 6)                   376                                                 3.29                                    91.0%     1, 6, 7, 9/33, ELISA (Enzymun; Boehringer Mannheim)                                                                1 m: NA/11                      Subjects with higher baseline CD4 counts were more likely to seroconvert and to have higher antibody titers
  CD4 \< 200/ 200+, 0/16                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  6 m: NA/9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  CD4 \< 200/ 200+, 0/13                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  7 m: NA/49,                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  CD4 \< 200/ 200+, 11/62                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  9 m: NA/52,                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  CD4 \< 200/ 200+, 9/67                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Neilsen et al\[[@B125]\]                             Pre-1996                 Randomized controlled trial, Australia                  Accelerated 2-dose, HIV-positive, 48                 HAVRIX 1440/ (0, 1)                   Mean 569                                            NA                                      NA        1, 3/20, ELISA (Enzymun; Boehringer Mannheim)                                                                      1 m: NA/80.0                    MSM only study; subjects with higher baseline CD4 counts were more likely to seroconvert and to have higher antibody titers; Vaccine schedule did not affect response; HIV-negative subjects had higher seroconversion rates and GMTs
  7 m: NA/93.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  CD4 ≤ 200, 64                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Standard 2-dose, HIV-positive, 42                    HAVRIX 1440/ (0, 6)      Mean 454                                                NA                                                   NA                                    1, 7/20, ELISA (Enzymun; Boehringer Mannheim)       1 m: NA/75.6                                                                                                                                                                                         
  7 m: NA/81.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  CD4 ≤ 200, 64                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Standard 2-dose, HIV-negative, 46                    HAVRIX 1440/ (0, 6)      NA                                                      NA                                                   NA                                    1, 7/20, ELISA (Enzymun; Boehringer Mannheim)       1 m: NA/90.2                                                                                                                                                                                         
  7 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Wilde et al\[[@B126]\]                               Pre-1995                 Prospective, United Kingdom                             Three mini-dose, HIV-positive hemophiliacs, 31       HAVRIX 720/ (0, 1, 6)                 Median 450 (IgG positive after 2 doses)             NA                                      0         1, 2, 7/20, EIA (SORIN Biomedica INCstar, Italy)                                                                   2 m: NA/29                      Hemophiliacs only (all anti-HCV positive); no patients with CD4 counts \< 170 cells/mm[3](#T7FN3){ref-type="table-fn"} seroconverted
  Median 335 (IgG positive after 3 doses)              7 m: NA/55                                                                                                                                                                                                                                                                                                                                                                                                                           
  Tilzey et al\[[@B127]\]                              Pre-1995                 Prospective, United Kingdom                             Three mini-dose, HIV-positive hemophiliacs, 25       HAVRIX 720/ (0, 1, 6)                 NA                                                  NA                                      NA        1, 2, 6, 7/20, ELISA (Boehringer-Mannheim)                                                                         1 m: NA/26                      Men only study; After 3 doses, all HIV-positive hemophiliacs with anti-HAV titers of \< 50 mIU/mL had CD4 counts \< 100 cells/mm[3](#T7FN3){ref-type="table-fn"}. HAVRIX 1440 was given as a 4^th^ booster dose to the 4 HIV vaccinees with anti-HAV \< 50 mIU/mL after 3 doses; only 1 subsequently developed anti-HAV \> 50 mIU/mL
  2 m: NA/50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  6 m: NA/47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  7 m: NA/76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Three mini-dose, HIV-negative hemophiliacs, 8        HAVRIX 720/ (0, 1, 6)    NA                                                      NA                                                   NA                                    1 m: NA/57                                                                                                                                                                                                                                               
  2 m: NA/86                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  6 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  7 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Three mini-dose, HIV-negative healthy controls, 25   HAVRIX 720/ (0, 1, 6)    NA                                                      NA                                                   NA                                    1 m: NA/100                                                                                                                                                                                                                                              
  2 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  6 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  7 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Hess et al\[[@B128]\]                                Pre-1994                 Prospective, controlled, Germany                        Three mini-dose, HIV-positive MSM, 26                HAVRIX 720/ (0, 1, 6)                 495                                                 NA                                      NA        1, 2, 6, 7/20, ELISA (SB Biologicals)                                                                              2 m: NA/78.6                    MSM only study; Seroconversion rates were independent of CD4 counts
  7 m: NA/76.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Three mini-dose, HIV-negative MSM, 20                HAVRIX 720/ (0, 1, 6)    NA                                                      NA                                                   NA                                                                                        2 m: NA/100                                                                                                                                                                                          
  7 m: NA/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Santagostino et al\[[@B129]\]                        Pre-1994                 NA, Italy                                               Three mini-dose, HIV-positive hemophiliacs, 47       HAVRIX 720 (0, 1, 6)                  NA                                                  NA                                      NA        1, 2, 7, 12/20                                                                                                     12 m: NA/76.6                   Hemophiliacs; Seroconversion rates were dependent on stage of HIV disease
  Three mini-dose, HIV-negative hemophiliacs, 66       HAVRIX 720 (0, 1, 6)     NA                                                      NA                                                   NA                                    NA                                                  12 m: NA/100                                                                                                                                                                                         

Number of HIV-positive individuals with baseline negative anti-HAV and data available;

Duration specified after the first dose when primary serological response was assayed;

Cut-off value of specific anti-HAV IgG used to define serological response;

Factors identified by multivariate analysis in HIV-positive individuals unless specified;

Percentage of patients with undetectable plasma HIV RNA load. cART: Combination of antiretroviral therapy; CIA: Chemiluminescence immunoassay; EIA: Enzyme immunoassay; ELISA: Enzyme linked immunosorbent assay; HAV: Hepatitis A virus; HCV: Hepatitis C virus; ITT: Intention-to-treat; NA: Not available; PVL: Plasma HIV RNA load; PP: Per-protocol.

The earliest studies of HAV vaccination in moderately to severely immunodeficient HIV-positive individuals preceded the licensure of the adult formulation of HAVRIX 1440 U wherein a triple-mini dosing scheme (3 pediatric doses of HAVRIX 720 U administered at 0, 1, and 6 mo) was applied to hemophiliac patients and MSM with or without HIV\[[@B127]-[@B129]\]. The seroconversion rates among such HIV-positive hemophiliacs and MSM at month 7 were consistently between 76.0%-76.9% and lower than their HIV-negative counterparts at 100%\[[@B127]-[@B129]\]. Later studies of HIV-positive individuals without hemophilia but with other risk factors such as MSM confirmed that the seroconversion rates following the recommended standard adult dosing schedule (2 doses of HAVRIX 1440 U or VAQTA 50 U administered 6-12 mo apart) were lower among HIV-positive adults compared to HIV-negative healthy adults, ranging from 48.6%-94.0%\[[@B122]-[@B125]\]. In a meta-analysis including 8 studies, combining a total of 458 HIV-positive patients, the overall rate of serological response to HAV vaccination was 64%\[[@B130]\]. In addition, the geometric mean titers (GMTs) of specific antibodies were also lower among HIV-positive individuals compared to the healthy population\[[@B115],[@B123],[@B127]\].

Overall, factors that correlated best with the poor response to HAV vaccination among HIV-positive individuals were surrogates of immune status such as low CD4 cell counts and high plasma HIV RNA loads at the time of vaccination as shown in Table [7](#T7){ref-type="table"}\[[@B115]-[@B129]\]. Other factors identified with low rates of seroconversion were HCV coinfection and tobacco smoking\[[@B116],[@B120]\]. Both male and female genders have been associated with seroconversion\[[@B121],[@B122]\].

While the vaccination effectiveness among HIV-positive individuals was mostly evaluated by seroconversion rates in the countries of low endemicities, the serological and clinical responses to HAV vaccination were rarely investigated in the outbreak setting. In a recent prospective observational study during the outbreak of acute hepatitis A among MSM in Taiwan, the overall seroconversion rate among HIV-positive MSM was 39.7% and 93.4% after receiving 1 dose and completing 2-dose series of HAV vaccination, respectively. Despite the delayed serological response, HAV vaccination had led to a 93% reduction in the risk of acute HAV infection among HIV-positive MSM during the outbreak setting. Higher CD4 cell counts were consistently correlated with higher seroconversion rates\[[@B131]\].

Studies published after the meta-analysis in 2006 made various attempts to augment the immune response to the inactivated HAV vaccine despite the aforementioned non-modifiable adverse factors. One attempt was by using a virosome-formulated HAV vaccine (Epaxal1, Berna Biotech Ltd.) to enhance the immune responses of 14 HIV-positive individuals compared to 64 healthy adults\[[@B132]\]. After a primary dose at day 1 and a booster dose 12 mo later, the seroconversion rates (anti-HAV IgG \> 20 mIU/mL) at month 13 were 91.7% and 100% in HIV-positive adults and in healthy adults, respectively. The GMTs of anti-HAV increased from 25.5 mIU/mL after the primary immunization to 659.2 mIU/mL after the booster dose in HIV-positive adults\[[@B132]\].

Other attempts were by increasing the number of doses of vaccine administered\[[@B115],[@B120],[@B121]\]. Two doses over 1 dose of HIV vaccine increased seroconversion rates in HIV-positive individuals\[[@B121],[@B123],[@B124]\]. There is less convincing evidence to show that 3 doses over 2 doses further increased seroconversion rates, possibly due to the smaller margin of benefit and the relatively larger sample size of adequate power needed to demonstrate the benefit. However, 2 studies showed trends of augmented responses in terms of seroconversion rates and GMTs by adding a booster dose at week 4 sandwiched between the first dose and the second dose at week 24\[[@B115],[@B120]\]. In the intention-to-treat (ITT) analysis, seroconversion at week 28 was observed in 82.6% *vs* 69.4% (*p =* 0.13) and at week 48 in 84.2% *vs* 78.1% (*p =* 0.23) in the 3-dose *vs* the 2-dose group for the French and Taiwanese studies, respectively.

When multiple doses have been used, the timing of the second and third dose did not affect immunogenicity in persons with limited immunodeficiency\[[@B125]\]. Hence, in the outbreak settings, an accelerated schedule, *i.e*., delivering the second or third booster dose at an interval of less than 3 mo from the first dose may be preferable although more studies are needed\[[@B131]\]. However, in HIV-positive individuals with more advanced immunodeficiency (CD4 \< 300 cells/mm^3^ or AIDS status), it may be preferable to wait for the CD4 count to recover before delivering the booster doses\[[@B123],[@B127]\]. In the most primitive example, of the 2 HIV-positive hemophiliacs with CD4 counts below 100 cells/mm^3^ who, after the third dose of HAVRIX 720 U, went on to receive a fourth booster dose of HAVRIX 1440 U, neither seroconverted\[[@B127]\].

To our knowledge, there is limited experience with using HAV vaccination as post-exposure prophylaxis in HIV-positive individuals. Although in healthy individuals, HAV vaccine has been demonstrated to be capable of protecting susceptible contacts with benefits of long-term protection when compared to passive immunization by immunoglobulins\[[@B133]\].

Durability of seroprotection and factors associated with persistent seroprotection
----------------------------------------------------------------------------------

In healthy adults following a primary 2-dose schedule, mathematical models indicate that anti-HAV antibodies may persist in \> 90% of vaccinees for 40 years or more\[[@B134]\]. In HIV-positive individuals, a slight decrease was observed over time; 88.6%-100% of responders were still seroprotected after 1 year\[[@B115],[@B120]\], 86.8%-90% after 3 years\[[@B135],[@B136]\], 85%-85.4% after 4 years\[[@B136],[@B137]\], and 75.5%-88.4% after 5 years\[[@B135],[@B136],[@B138]\]. Percentages of seroprotection at the end of 5 years of follow-up were 78.9% *vs* 76.4% by ITT analysis (*p =* 0.61) (Table [8](#T8){ref-type="table"})\[[@B135]-[@B138]\]. GMTs were significantly higher throughout each consecutive year with the 3-dose schedule as compared to the standard 2-dose schedule\[[@B136]\]. Factors associated with persistent seroprotection include virologic suppression at vaccination and maintained lower levels of HIV viremia as denoted by time-updated plasma HIV RNA load\[[@B135],[@B137]\], 3-dose compared to 2-dose schedule (adjusted odds ratio 3.36; 95%CI: 1.14-9.93), acute syphilis and absence of acute hepatitis C\[[@B136],[@B138]\].

###### 

Long-term response rates and predictors of sustained seroprotection after hepatitis A virus vaccination in human immunodeficiency virus-positive patients

  **Ref**.                          **Dates**           **Design/Country**             **No. of patient[1](#T8FN1){ref-type="table-fn"}**   **HAV/dosing schedules (mo)**       **CD4, cells/mm[3](#T8FN3){ref-type="table-fn"}**   **PVL, log~10~, copies/mL**           **ART (%)**   **Timing of assay[2](#T8FN2){ref-type="table-fn"}, yr/cut-off[3](#T8FN3){ref-type="table-fn"}, mIU/mL/Assay**   **Response rate (%): ITT/PP**   **Predictors of persistent response and comments[4](#T8FN4){ref-type="table-fn"}**
  --------------------------------- ------------------- ------------------------------ ---------------------------------------------------- ----------------------------------- --------------------------------------------------- ------------------------------------- ------------- --------------------------------------------------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------------------------------------
  Cheng et al\[[@B136]\]            2010-2015           Prospective, Taiwan            Primary responders:                                  HAVRIX 1440 U/                      560/415                                             2.5/2.8                               70/56         2, 3, 4, 5/20                                                                                                   At 1.5 yr:                      MSM only study; 3-doses over 2-dose, syphilis, lack of acute HCV
  2 doses, 110                      2 doses (0, 6)                                                                                                                              ELISA (ETIAB- HAVK PLUS)                            2 doses: 90.0/93.4                                                                                                                                                                                  
  3 doses, 185                      3 doses (0, 1, 6)                                                                                                                           3 doses: 87.0/94.7                                                                                                                                                                                                                                      
  Non-                                                  470/315                        2.9/3.3                                              59/63                               At 5 yr:                                                                                                                                                                                                                                                
  responders:                                                                                                                                                                   2 doses: 76.4/88.4                                                                                                                                                                                                                                      
  2 doses, 16                                                                                                                                                                   3 doses: 78.9/94.2                                                                                                                                                                                                                                      
  3 doses, 23                                                                                                                                                                                                                                                                                                                                                                                                                           
  Kernéis et al\[[@B137]\]          2006-2009           Prospective, France            Primary responders:                                  HAVRIX 1440/                        362                                                 62%[5](#T8FN5){ref-type="table-fn"}   NA            7, 43/20                                                                                                        At 3.7 yr:                      PVL \< 50 copies/mL at time of last vaccine dose and a short duration of HIV infection
  71 (52)                           2 doses (0, 6)      ELISA (ETIAB-                  Overall: 61.9/84.6                                                                                                                                                                                                                                                                                                                               
                                    3 doses (0, 1, 6)   HAVK PLUS)                                                                                                                                                                                                                                                                                                                                                                      
  Jablonowska et al\[[@B138]\]      2004                Prospective, Poland            Primary responders:                                  HAVRIX 1440                         450                                                 NA                                    37            1.5, 5/20                                                                                                       At 1.5 yr:                      Lack of co-infection with HCV
  66                                (0, 6)              CIA (Cobas, Roche)             75.8/81.9                                                                                                                                                                                                                                                                                                                                        
                                                                                       At 5 yr:                                                                                                                                                                                                                                                                                                                                         
                                                                                       56.1/75.5                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Crum-Cianflone et al\[[@B135]\]   1996-2003           Retrospective, United States   116                                                  Vaqta 50 or HAVRIX 1440 (0, 6-18)   Median, 467                                         50%[5](#T8FN5){ref-type="table-fn"}   62            3, 6-10/10                                                                                                      At 3 yr:                        Lower PVL; PVL \< 400 copies/mL
  90                                                                                                                                                                                                                                                                                                                                                                                                                                    
  At 6-10 yr:                                                                                                                                                                                                                                                                                                                                                                                                                           
  85                                                                                                                                                                                                                                                                                                                                                                                                                                    

Number of vaccinees with primary seroconversion after the last dose of vaccine; (figure in parentheses is the number of vaccinees with primary conversion and subsequent sera for follow-up of antibody persistence);

Duration specified after the first dose when primary serological response was assayed;

Cut-off value of specific anti-HAV IgG used to define serological response;

Factors identified by multivariate analysis in HIV-positive individuals unless specified;

Percentage of patients with undetectable plasma HIV RNA load. ART: Antiretroviral therapy; CIA: Chemiluminescence immunoassay; ELISA: Enzyme linked immunosorbent assay; HAV: Hepatitis A virus; HCV: Hepatitis C virus; ITT: Intention-to-treat; MSM: Men who have sex with men; NA: Not available; PVL: Plasma HIV RNA load; PP: Per-protocol.

Given the lower initial antibody levels, the apparent waning of antibody levels and the increasing life expectancy of HIV-positive individuals, post-vaccination booster doses may be necessary to maintain anti-HAV levels after 10 years in HIV-positive individuals in the absence of virologic suppression\[[@B111]\]. Currently, only the British HIV Association (BHIVA) recommends delivering booster vaccination every 10 years whilst other health authorities recommend regular monitoring of anti-HAV IgG and booster vaccinations only if at continued risk after seroconversion (Table [6](#T6){ref-type="table"})\[[@B111]-[@B114]\]. However, among immunocompetent hosts, memory responses to HAV may exist even in the absence of detectable antibodies\[[@B139]\], and in the era of cART, the same may apply to HIV-positive patients with immune reconstitution\[[@B131]\]. Nevertheless, the strategies of booster HAV vaccination to those with waning immunity or non-responders need more studies to confirm the effectiveness.

Vaccine safety
--------------

Serious adverse events following HAV vaccination in HIV-positive individuals are rare and not more common among HIV-positive individuals compared to HIV-negative vaccinees. HAV vaccination does not have a significant impact on plasma HIV RNA load, progression to AIDS, or CD4 cell count\[[@B123],[@B124],[@B130]\].

CONCLUSION
==========

In this review, we have found that, in developed countries of low HAV endemicity, HIV-positive individuals remain susceptible to HAV infection because of low adherence to recommended HAV vaccination, at-risk sexual behaviors, and injecting drug use, as demonstrated by the recent outbreaks of acute HAV infections among MSM and IDUs in Taiwan and Israel, respectively\[[@B71],[@B88]\], despite the implementation of HAV vaccination programs in children. Serological response rates to the recommended 2-dose HAV vaccination are lower in HIV-positive individuals than HIV-negative individuals; an additional dose of HAV vaccine may improve serological responses and durability of seroprotection in HIV-positive individuals with initial low CD4 cell counts. While clinical trials are warranted to confirm the HAV vaccine efficacy in the outbreak setting of acute HAV infection, the recent observational study suggested that implementation of the 2-dose HAV vaccination was effective in preventing acute HAV infection among MSM. With ongoing improvements in survival and quality of life with modern cART, the importance of awareness of and adherence to HAV vaccination recommendations cannot be overemphasized among health care providers as well as at-risk populations.
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